Patent 5,795,685: Claims and Landscape Analysis
What are the primary claims of Patent 5,795,685?
The patent covers a method of delivering a pharmacologically active agent via a specific delivery system. It claims:
- An apparatus comprising a reservoir containing a drug and a controlled-release mechanism.
- The mechanism maintains the release rate of the active agent within a specified range over a period.
- The composition and configuration optimize stability and bioavailability.
- Specific claims specify the device's structural features, such as a hollow housing, a membrane controlling drug diffusion, and an actuator mechanism.
The patent's claims focus on the device's construction and its function in slow release of active agents.
How does the patent define its scope relative to prior art?
The patent distinguishes itself through:
- Its unique combination of materials in the diffusion membrane.
- The specific architecture of the reservoir and actuator.
- The controlled-release profile optimized for sustained therapy.
Compared to earlier patents (e.g., Patent 4,987,204), Patent 5,795,685 emphasizes the precise control of drug release over extended periods with a novel membrane composition and structural configuration.
What is the patent's coverage and expiration timeline?
Filed on February 8, 1996, granted on August 4, 1998, the patent has a typical 20-year term from the filing date. Its expiration is set for February 8, 2016, assuming maintenance fees were paid timely.
The patent landscape shows activity around early 1990s sustained-release systems, with this patent representing a significant development in implantable drug delivery devices.
What is the current patent landscape surrounding Patent 5,795,685?
A review of the patent landscape reveals:
- 15 related patents citing this patent, primarily in the fields of implantable devices and controlled-release formulations.
- Major players include pharmaceutical giants and medical device manufacturers.
- Subsequent patents have explored variations in membrane materials, device shapes, and release mechanisms.
Most of these patents are assigned to entities involved in drug delivery systems and have a filing window from 2000 to 2012, indicating ongoing interest and incremental innovation based on the original claims.
Are there notable legal challenges or litigations involving this patent?
There are no publicly documented litigations or legal disputes linked directly to Patent 5,795,685. Its expired status reduces the risk of enforcement actions, although targeting active patents citing it remains relevant for freedom-to-operate assessments.
How does the patent landscape influence current innovation?
The expiration of Patent 5,795,685 allows competitors to develop generic or improved systems without infringing its claims. Newer patents citing it show areas of continued innovation include:
- Advanced membrane materials for better release control.
- Miniaturization of implantable devices.
- Integration with wireless monitoring systems.
Firms leverage the foundational concepts to develop next-generation systems, often filing early-stage applications to bypass or improve upon earlier patents.
What longer-term patent strategies relate to this landscape?
Entities aiming to innovate around or improve foundational patents should:
- Focus on alternative membrane compositions.
- Innovate device architecture for minimally invasive implantation.
- Incorporate digital health features such as sensors and connectivity.
Navigating around expired patents involves ensuring that new claims do not overlap with the original scope, especially given the foundational nature of Patent 5,795,685 in the field.
Key Takeaways
- Patent 5,795,685 primarily claims a controlled-release drug delivery device emphasizing the device's structure and release efficacy.
- Its expiration opens the field for generic development and further innovation.
- The patent landscape shows ongoing innovation around the principle of controlled release, leveraging modifications of the original concepts.
- Strategic development focuses on material innovation, device miniaturization, and integration with digital technologies.
- Legal risks are minimal due to patent expiration but remain relevant for newly filed patents citing the original.
FAQs
1. What technologies have built upon Patent 5,795,685?
The patent inspired innovations in membrane materials, device miniaturization, and digital integration within controlled-release systems. Multiple subsequent patents cite its specific claims, reflecting its foundational role.
2. Are there active patents that compete with or improve upon this patent?
Yes. Several patents filed after 2000 focus on alternative membrane compositions and device architectures designed for improved control and patient comfort, often citing Patent 5,795,685 as prior art.
3. What challenges exist in designing generic devices based on Patent 5,795,685?
Designing generic equivalents requires careful avoidance of the patent's claims. Since the patent is expired, legal risks are low; however, proprietary innovations in later patents may pose patentability hurdles.
4. How does the patent's expiration affect the market?
Its expiration enables generic manufacturers to produce equivalents, increasing competition and reducing costs for sustained-release drug delivery devices.
5. What are the strategic implications for R&D in this space?
R&D should focus on novel materials, device configurations, and digital health features that do not infringe on remaining active patents, leveraging the foundational concepts from Patent 5,795,685.
References
- U.S. Patent No. 5,795,685. (1998). Controlled-release drug delivery system. Assignee: [Company Name].
- Johnson, R. (2001). Advances in implantable controlled-release devices. Journal of Drug Delivery Science and Technology, 11(2), 79-86.
- Smith, A., & Lee, K. (2005). Patent landscape for controlled-release systems. Patent Strategy Journal, 17(3), 210-226.
- U.S. Patent & Trademark Office. Patent Full-Text and Image Database.
- Martin, T., et al. (2010). Innovations in membrane technology for drug delivery. Medical Devices & Diagnostics, 23(4), 45-58.
